XM does not provide services to residents of the United States of America.
B
B

Boliden

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

RBC upgrades Boliden, sees challenges fading away

BUZZ-RBC upgrades Boliden, sees challenges fading away ** RBC upgrades rating on Boliden BOL.ST to "sector perform" from "underperform", noting a positive impact of higher base metal prices , the restart of the Tara zinc mine ** "We see a clearer path towards operational stability", the broker says, adding the Swedish mining and smelting group was
B

BNP Paribas, Renault, Soitec

EUROPE RESEARCH ROUNDUP-BNP Paribas, Renault, Soitec May 29 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including BNP Paribas, Renault and Soitec, on Wednesday. HIGHLIGHTS * BNP Paribas BNPP.PA : HSBC raises target price to EUR 90 from EUR 73 * Darktrace Plc DARK.L : Northland Capital cuts to market perform * Mitchells & Butlers MAB.L : HSBC raises target price to 345p from 320p * Renault RENA.PA : Goldman Sachs raises to buy from neutra
A
A
B
B
C
E
I
K
M
N
R
S
T
U
A
M
N
S
S
S
T
U

Top of the Street: Mondi, Boliden, Akzo Nobel, BAE Systems, Yara

BUZZ-Top of the Street: Mondi, Boliden, Akzo Nobel, BAE Systems, Yara A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** 5-star ranked BofA's analyst Benjamin Heelan downgrades British defence company BAE Systems BAES.L to "neutral" from "buy," seeing limited near-term valuation upside after a "very strong run" ** UBS cuts Boliden BOL.ST to "sell" from "neutral," as the broker flags challenges to metal prices and elevated capex risk for the Swedish smelting
B
B
J
M
A
Y

UBS cuts Boliden to 'sell' on lower prices, higher capex risks

BUZZ-UBS cuts Boliden to 'sell' on lower prices, higher capex risks ** UBS cuts Boliden BOL.ST to "sell" from "neutral", warning of challenges to metal prices, elevated capex risk for the Swedish smelting and mining group ** The Boliden stock slides 2.6% to SEK 360 ** The broker notes the 40% decrease of zinc treatment charges decrease in 2024 that
B

Adecco Group, Centrica, UBS

EUROPE RESEARCH ROUNDUP-Adecco Group, Centrica, UBS May 8 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adecco Group, Centrica and UBS, on Wednesday. HIGHLIGHTS * Adecco Group AG ADEN.S : RBC raises to outperform from sector perform * Centrica CNA.L : UBS raises to buy from neutral * Direct Line Insurance DLGD.L : Morgan Stanley resumes coverage with equal-weight rating * Lindt & Spruengli LISN.S : Barclays raises to equal weight
A
A
A
A
A
A
B
B
B
B
B
C
D
E
G
H
H
I
K
L
L
L
S
S
S
V
A
A
B
B
D
D
M

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.